PROMENADE: PembROlizuMab for early ER-low/HER2breast caNcer, reAlworlD frEnch cohort F. Cherifi1, L. Cabel2, C. Bousrih3, E. Volant4, F. Dalenc5, B. Mery6, M. Auvray Kuentz7, M. Alexandre8, L. Benistant9, M. Leheurteur10, C. Bailleux11, M. Debled12, J-S. Frenel13, D. Loirat2, F.C. Bidard2, S. Aho14, A. Glenet15, J.T.L. Ribeiro Mourato3, F. Christy16, G. Emile1 1Breast Cancer Unit, Centre Francois Baclesse, Caen, CEDEX 4, France 2Medical Oncology, 

Institut Curie, Paris, CEDEX 14, France, 3Breast unit, Gustave Roussy - Cancer Campus, Villejuif, France 4Oncology, Cancéropôle Grand Ouest - CHU Nantes Immeuble Deurbroucq, Nantes, France, 5Medical oncology, Oncopole Claudius Regaud- IUCT, Toulouse, France, 6Oncology, Center Leon Berard, Lyon, France, 7 Oncology Center Eugène Marquis, Rennes, France, 8Medical Oncology, ICM - Institut du Cancer de Montpellier, Montpellier, France, 9Oncology, ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, France, 10Oncology, Centre Henri Becquerel, Rouen, CEDEX 1, France, 11Oncology, Centre Anticancer Antoine Lacassagne, Nice, France, 12Institute Bergonié - Centre Régional de Lutte Contre le Cancer Bordeaux,France 13Medical Oncology Department, ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain,France, 14Institut de Cancérologie de Lorraine, Nancy, France 15Oncology, IUCT Oncopole, Toulouse, France, 16Clinical Research, Centre Francois Baclesse, Caen, Cedex, France, 

DECLARATION OF INTERESTS François Cherifi, M.D. Research grant : Novartis Honoraria or consultations fees for public speaking : AstraZeneca, MSD, Roche, Gilead Registration fees and accommodations : Chugai, AstraZeneca, MSD, Roche, Gilead, Pharmaand Network membership : ESMO and Oncodistinct 

f.cherifi@baclesse.unicancer.fr François Baclesse Cancer Center, Caen, France 

Background ❖ 

ESMO and ASCO/CAP guidelines recommend a cut-off of ER expression <1% to define TNBC In France and other countries the cut-off for TNBC is set <10% 

❖ 

BC with ER 1%-9% expression, also called “ER-low BC”, is a rare subtype Represents less than 10% of TNBC and approximately 5% of ER+ Pathological features more similar to ER <1% than ER >10% (e.g. basal like) 1 

❖ 

Swedish cohort study2 : ER low population had a similar prognosis to the triple negative population Same DFS and OS American cohort study3: Clear benefit for adjuvant endocrine therapy for ER-low BC 

❖ 

ER-low BC are treated like TNBC in France but there is a lack of data concerning this population in the neoadjuvant setting 1 Y Ke-Da et al Cancer Communications V41, I10, 2021 2 A Balazs et al The Lancet Regional Health-Europe V40, 2024 3 GM Yee Choong et al Journal of Clinical Oncology, V42,N16, 2024 

Background KEYNOTE-522 (NCT03036488) 

KEYNOTE-756 (NCT03725059) 

100 

100 

TNBC 

90 80 

80 64.8 

60 

70 51.2 

50 40 

pCR % 

pCR % 

70 

ER+ 

90 

60 50 40 

30 

30 

20 

20 

10 

10 

0 

0 Pembrolizumab–chemo 

Placebo-chemo 

Standard of Care 

24.3 15.6 

Pembrolizumab-chemo 

Placebo-chemo 

F Cardoso et al Annals of Oncology V34, S2, 2023 P Schmid et al N Engl J Med, V382 NO9, 2020 

METHODS Retrospective real-life study 12 Comprehensive Cancer Centers in 13 cities in France 

Inclusion Criteria: • All patients receiving KEYNOTE 522 regimen • Since its availability in march 2022 • Estrogen and/or progesterone receptor low (1-9%) • HER2 negative (0, 1+, 2+ ISH neg) 

Rouen 

Caen Rennes 

Curie Strasbourg 

Gustave Angers Roussy 

Nantes 

Bordeaux 

Lyon 

Primary Objective: pCR (ypT0/isN0 or RCB 0) rate Toulouse Nice Montpellier 

RESULTS General characteristics Number of patients 

114 

Age - Median (min-max) 49 (26-80) Missing 2 (1.8%) Menopausal status - n (%) Pre 64 (57%) Post 48 (43%) Missing 2 (1.8%) Tumor size - n (%) <T2 12 (11%) 

≥T2 Node - n (%) N0 N ≥1 

102 (89%) 58 (51%) 56 (49%) 

Pathology Histology - n (%) Ductal 102 (90%) Lobular 2 (2%) Other 9 (8%) Missing 1 (0.9%) SBR grade - n (%) II 15 (14%) III 95 (86%) Missing 4 (3.5%) KI67 - Mean (SD) 61 (24) Missing 15 (13.2%) Endocrine receptors - n (%) ER-/PR+ 37 (32%) ER+/PR66 (58%) ER+/PR+ 11 (10%) HER2 – n (%) 0 57 (50%) 1 35 (31%) 2 (ISH neg) 22 (19%) 

Treatment NACT* completed- n (%) 

83 (75%) 

Missing Surgery - n (%) Surgery type - n (%) Lumpectomy Mastectomy Not done (PD) Other Nodal intervention - n (%) Sentinel lymph node Axillary dissection Not done (PD) Other 

4 (3.5%) 113 (99%) 62 (54.3%) 50 (44%) 1 (0.8%) 1 (0.8%) 57 (50%) 54 (47%) 1 (0.8%) 2 (1.7%) 

RESULTS General characteristics Number of patients 

114 

Age - Median (min-max) 49 (26-80) Missing 2 (1.8%) Menopausal status - n (%) Pre 64 (57%) Post 48 (43%) Missing 2 (1.8%) Tumor size - n (%) <T2 12 (11%) 

≥T2 Node - n (%) N0 N ≥1 

102 (89%) 58 (51%) 56 (49%) 

Pathology Histology - n (%) Ductal 102 (90%) Lobular 2 (2%) Other 9 (8%) Missing 1 (0.9%) SBR grade - n (%) II 15 (14%) III 95 (86%) Missing 4 (3.5%) KI67 - Mean (SD) 61 (24) Missing 15 (13.2%) Endocrine receptors - n (%) ER-/PR+ 37 (32%) ER+/PR66 (58%) ER+/PR+ 11 (10%) HER2 – n (%) 0 57 (50%) 1 35 (31%) 2 (ISH neg) 22 (19%) 

Treatment NACT* completed- n (%) 

83 (75%) 

Missing Surgery - n (%) Surgery type - n (%) Lumpectomy Mastectomy Not done (PD) Other Nodal intervention - n (%) Sentinel lymph node Axillary dissection Not done (PD) Other 

4 (3.5%) 113 (99%) 62 (54.3%) 50 (44%) 1 (0.8%) 1 (0.8%) 57 (50%) 54 (47%) 1 (0.8%) 2 (1.7%) 

RESULTS 

pCR rate with KEYNOTE-522 regimen in ER-low BC 

80 70 

RCB 

n (%) 

0 

85 (75 %) 

1 

9 (8 %) 

2 

12 (11 %) 

20 

3 

7 (6 %) 

10 

Progressive disease 

% of pCR 

60 50 40 

75% 64% 

30 

24% 

1 (1 %) 

0 PROMENADE 

KEYNOTE-522 

KEYNOTE 756 

RESULTS 

pCR rate with NACT ER-low 

80 

TNBC 

70 

% of pCR 

60 50 

40 

75% 64% 

30 

ER+ 

20 

24% 

10 0 PROMENADE Data are not intended to be directly comparative 

KEYNOTE-522 

KEYNOTE 756 

TAKE HOME MESSAGE ❖ Tumors with ER-low status have: ❖ A high rate of pCR after KEYNOTE 522 regimen ❖ Respond differently than ER-positive and more like Triple-negative BC ❖ KEYNOTE 522 regimen seems to be useful for this population 

What is the best treatment in the adjuvant setting ? 

Acknowledgements Thanks to…. ➢ All patients and their families participating in this study ➢ All investigators and centers ➢ 2024 ESMO organization committee ➢ For your attention European Society for Medical Oncology (ESMO) Via Ginevra 4, CH-6900 Lugano T. +41 (0)91 973 19 00 esmo@esmo.org esmo.org 

 